Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule.

Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, Kiss S, Flaxel C, Collins M, Miller J, Hauswirth W, Maclachlan T, Wadsworth S, Scaria A.

Mol Ther. 2011 Feb;19(2):260-5. doi: 10.1038/mt.2010.230. Epub 2010 Oct 26.

2.
3.

Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.

Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, Veres G, Scaria A, Andrews L, Wadsworth S.

Mol Ther. 2011 Feb;19(2):326-34. doi: 10.1038/mt.2010.258. Epub 2010 Nov 30.

4.

AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization.

Zhang X, Das SK, Passi SF, Uehara H, Bohner A, Chen M, Tiem M, Archer B, Ambati BK.

Mol Ther. 2015 Feb;23(2):226-34. doi: 10.1038/mt.2014.199. Epub 2014 Oct 13.

5.

Development of gene therapy for treatment of age-related macular degeneration.

Askou AL.

Acta Ophthalmol. 2014 Jul;92 Thesis3:1-38. doi: 10.1111/aos.12452.

6.

Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration.

Lambert NG, Zhang X, Rai RR, Uehara H, Choi S, Carroll LS, Das SK, Cahoon JM, Kirk BH, Bentley BM, Ambati BK.

Exp Eye Res. 2016 Apr;145:248-257. doi: 10.1016/j.exer.2016.01.009. Epub 2016 Jan 13.

PMID:
26775053
7.

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.

Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, Scaria A.

Gene Ther. 2009 Jan;16(1):10-6. doi: 10.1038/gt.2008.115. Epub 2008 Jul 17.

PMID:
18633446
8.

Reduction of choroidal neovascularization in mice by adeno-associated virus-delivered anti-vascular endothelial growth factor short hairpin RNA.

Askou AL, Pournaras JA, Pihlmann M, Svalgaard JD, Arsenijevic Y, Kostic C, Bek T, Dagnaes-Hansen F, Mikkelsen JG, Jensen TG, Corydon TJ.

J Gene Med. 2012 Nov;14(11):632-41. doi: 10.1002/jgm.2678.

PMID:
23080553
9.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.

Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA.

Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Erratum in: Lancet. 2017 Jul 1;390(10089):28.

PMID:
28526489
10.

Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.

Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW.

Mol Vis. 2008 Sep 24;14:1760-9.

12.

Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.

Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW.

Arch Ophthalmol. 2002 Mar;120(3):338-46.

PMID:
11879138
13.

Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.

Gu L, Chen H, Tuo J, Gao X, Chen L.

Exp Eye Res. 2010 Sep;91(3):433-9. doi: 10.1016/j.exer.2010.06.019. Epub 2010 Jul 1.

PMID:
20599960
14.

Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.

Crespo-Garcia S, Corkhill C, Roubeix C, Davids AM, Kociok N, Strauss O, Joussen AM, Reichhart N.

Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):4997-5006. doi: 10.1167/iovs.16-21283.

PMID:
28979997
15.
16.

Long-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularization.

El Sanharawi M, Touchard E, Benard R, Bigey P, Escriou V, Mehanna C, Naud MC, Berdugo M, Jeanny JC, Behar-Cohen F.

Gene Ther. 2013 Nov;20(11):1093-103. doi: 10.1038/gt.2013.36. Epub 2013 Jun 27.

PMID:
23804076
17.

Suppression of choroidal neovascularization by vasohibin-1, a vascular endothelium-derived angiogenic inhibitor.

Wakusawa R, Abe T, Sato H, Sonoda H, Sato M, Mitsuda Y, Takakura T, Fukushima T, Onami H, Nagai N, Ishikawa Y, Nishida K, Sato Y.

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3272-80. doi: 10.1167/iovs.10-6295.

PMID:
21345982
19.

Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys.

Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, Lee SY, Yeo IY, Mathur R, Ho JE, Pineda P, Barathi A, Ang CL, Constable IJ, Rakoczy EP.

Mol Ther. 2005 Oct;12(4):659-68.

20.

Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.

Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR.

Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2309-17.

PMID:
10892878

Supplemental Content

Support Center